Juliane HÃ¶rner-Rieber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9053695/publications.pdf

Version: 2024-02-01

54	840	430874	580821
papers	citations	18 h-index	25 g-index

56	56	56	944
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany. Strahlentherapie Und Onkologie, 2020, 196, 691-698.	2.0	44
2	Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. Radiotherapy and Oncology, 2017, 125, 317-324.	0.6	41
3	Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. International Journal of Radiation Oncology Biology Physics, 2020, 107, 579-586.	0.8	40
4	Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). International Journal of Radiation Oncology Biology Physics, 2021, 109, 1311-1324.	0.8	37
5	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiotherapy and Oncology, 2021, 159, 146-154.	0.6	37
6	Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiation Oncology, 2020, 15, 30.	2.7	36
7	Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis . Cancer Management and Research, 2019, Volume 11, 789-801.	1.9	35
8	Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. Clinical Lung Cancer, 2019, 20, e667-e677.	2.6	33
9	Palliative Radiotherapy for Leptomeningeal Carcinomatosisâ€“Analysis of Outcome, Prognostic Factors, and Symptom Response. Frontiers in Oncology, 2018, 8, 641.	2.8	32
10	Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Management and Research, 2018, Volume 10, 6563-6569.	1.9	31
11	Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Tumors: Initial Clinical Experience and Patient-Reported Outcomes. Frontiers in Oncology, 2021, 11, 610637.	2.8	31
12	A practical implementation of risk management for the clinical introduction of online adaptive Magnetic Resonance-guided radiotherapy. Physics and Imaging in Radiation Oncology, 2021, 17, 53-57.	2.9	28
13	Patient positioning and immobilization procedures for hybrid MR-Linac systems. Radiation Oncology, 2021, 16, 183.	2.7	26
14	Whole brain radiation therapy alone versus radiosurgery for patients with 1â€“10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial. Trials, 2018, 19, 388.	1.6	25
15	Response rates and recurrence patterns after low-dose radiotherapy with 4â€¯Gy in patients with low-grade lymphomas. Strahlentherapie Und Onkologie, 2018, 194, 454-461.	2.0	22
16	Estimation of the Î±/Î² ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. Radiotherapy and Oncology, 2020, 142, 210-216.	0.6	22
17	Outcome and prognostic factors in single brain metastases from small-cell lung cancer. Strahlentherapie Und Onkologie, 2018, 194, 98-106.	2.0	21
18	Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung. Frontiers in Oncology, 2020, 10, 564857.	2.8	19

#	Article	IF	Citations
19	Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer. Frontiers in Oncology, 2020, 10, 987.	2.8	19
20	Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations. Frontiers in Oncology, 2021, 11, 757031.	2.8	17
21	Second breast conserving therapy after ipsilateral breast tumor recurrence â€“ a 10-year experience of re-irradiation. Journal of Contemporary Brachytherapy, 2019, 11, 312-319.	0.9	15
22	Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancerâ€"Cross-Sectional Study of Eligibility and Administration Rates. Frontiers in Oncology, 2020, 10, 586449.	2.8	15
23	Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Frontiers in Oncology, 2020, 10, 989.	2.8	15
24	Accelerated Partial Breast Irradiation: A New Standard of Care?. Breast Care, 2020, 15, 136-147.	1.4	14
25	Quality assurance for onâ€table adaptive magnetic resonance guided radiation therapy: A software tool to complement secondary dose calculation and failure modes discovered in clinical routine. Journal of Applied Clinical Medical Physics, 2022, 23, e13523.	1.9	14
26	Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison. Strahlentherapie Und Onkologie, 2019, 195, 677-687.	2.0	13
27	Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiation Oncology, 2020, 15, 235.	2.7	13
28	Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. Clinical Lung Cancer, 2020, 22, 332-340.e3.	2.6	11
29	Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3). Radiation Oncology, 2022, 17, .	2.7	11
30	SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. Radiotherapy and Oncology, 2022, 168, 106-112.	0.6	10
31	Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancerâ€"Experiences from a Single Institution. Frontiers in Oncology, 2017, 7, 215.	2.8	9
32	Acute Toxicity and Early Oncological Outcomes After Intraoperative Electron Radiotherapy (IOERT) as Boost Followed by Whole Breast Irradiation in 157 Early Stage Breast Cancer Patientsâ€"First Clinical Results From a Single Center. Frontiers in Oncology, 2019, 9, 384.	2.8	9
33	Radiation-induced contrast enhancement following proton radiotherapy for low-grade glioma depends on tumor characteristics and is rarer in children than adults. Radiotherapy and Oncology, 2022, 172, 54-64.	0.6	9
34	Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. Strahlentherapie Und Onkologie, 2020, 196, 705-714.	2.0	8
35	Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes. Strahlentherapie Und Onkologie, 2022, 198, 56-65.	2.0	8
36	Innovative radiation oncology TogetherÂâ€“ Precise,ÂPersonalized,ÂHuman. Strahlentherapie Und Onkologie, 2021, 197, 1043-1048.	2.0	7

#	Article	IF	Citations
37	Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial. Radiotherapy and Oncology, 2021, 163, 165-176.	0.6	7
38	MR-guided radiotherapy of moving targets. Der Radiologe, 2021, 61, 39-48.	1.7	6
39	MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?. Frontiers in Oncology, 2020, 10, 615697.	2.8	6
40	Fatigue following radiotherapy of low-risk early breast cancer â€“ a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419). Radiation Oncology, 2020, 15, 134.	2.7	5
41	Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. Johnâ€™s wort skin oil. Strahlentherapie Und Onkologie, 2021, 197, 644-649.	2.0	5
42	Effectiveness and Toxicity of Fractionated Proton Beam Radiotherapy for Cranial Nerve Schwannoma Unsuitable for Stereotactic Radiosurgery. Frontiers in Oncology, 2021, 11, 772831.	2.8	5
43	Influence of photon, proton and carbon ion irradiation on differentiation, maturation and functionality of dendritic cells. Frontiers in Bioscience - Scholar, 2022, 14, 1.	2.1	5
44	Validation of Nine Different Prognostic Grading Indexes for Radiosurgery of Brain Metastases in Breast Cancer Patients and Development of an All-Encompassing Prognostic Tool. Frontiers in Oncology, 2020, 10, 1557.	2.8	4
45	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors. Cancers, 2020, 12, 2862.	3.7	3
46	Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors. Tumori, 2023, 109, 112-120.	1.1	3
47	Return to Work, Fatigue and Cancer Rehabilitation after Curative Radiotherapy and Radiochemotherapy for Pelvic Gynecologic Cancer. Cancers, 2022, 14, 2330.	3.7	3
48	Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation. International Journal of Gynecological Cancer, 2022, 32, 172-180.	2.5	2
49	Postoperative Radiotherapy for Endometrial Cancer in Elderly (â‰¥80 Years) Patients: Oncologic Outcomes, Toxicity, and Validation of Prognostic Scores. Cancers, 2021, 13, 6264.	3.7	2
50	Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Cancers, 2022, 14, 2409.	3.7	2
51	Adjuvant Radiation Therapy for Male Breast Cancerâ€”A Rare Indication?. Cancers, 2020, 12, 3645.	3.7	1
52	Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands. Cancers, 2021, 13, 124.	3.7	1
53	Screening and Psycho-Oncological Support for Patients With Head and Neck Cancer and Brain Malignancies Before Radiotherapy With Mask Fixation: Results of a Feasibility Study. Frontiers in Psychology, 2021, 12, 760024.	2.1	1
54	Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patientsâ€™ and Physiciansâ€™ Assessment from the Randomized IMRT-MC2 Trial. Cancers, 2022, 14, 3010.	3.7	1